City Drug House Exporters | Hepatitis Medicines Supplier to Washington, USA, INDIA
City Drug House Exporters supplies and exports high-quality hepatitis medicines from India to Washington, USA with trusted pharma solutions and timely global delivery.
Velakast (400 mg Sofosbuvir / 100 mg Velpatasvir) is a direct-acting antiviral (DAA) fixed-dose combination medication used to treat chronic Hepatitis C virus (HCV) infection across all six major genotypes (1–6).
Mechanism of ActionThe combination works synergistically to disrupt viral replication at two distinct stages in the Hepatitis C virus lifecycle:
Sofosbuvir (400 mg): A nucleotide analog that acts as a defective substrate for the HCV NS5B RNA-dependent RNA polymerase. It prematurely terminates RNA chain synthesis, effectively halting viral replication.
Velpatasvir (100 mg): A targeted inhibitor of the HCV NS5A protein. This structural protein is essential for viral replication and assembly. By blocking NS5A, Velpatasvir prevents the virus from multiplying and assembling.
Pharmacokinetics :
Administration & Absorption: Taken orally once daily with or without food.
Metabolism: Sofosbuvir is rapidly metabolized into its active form within the liver. Velpatasvir is extensively metabolized in the liver, primarily via the CYP2B6, CYP2C8, and CYP3A4 enzyme pathways.
Excretion: The majority of the Sofosbuvir dose is excreted by the kidneys (as a metabolite), while Velpatasvir is mostly eliminated in the feces.
Indications & Usage :
Velakast is typically prescribed as a once-daily 28-tablet regimen, running for 12 or 24 weeks depending on the presence of liver cirrhosis, prior treatment history, and HCV genotype. It is widely used and approved by authoritative bodies like the U.S. FDA for adults and children over the age of 3.
Important Precautions :
Drug Interactions: Co-administration with amiodarone can cause severe symptomatic bradycardia. Caution is also advised when combining with certain anticonvulsants, statins, and proton pump inhibitors (PPIs), as they can affect blood levels of Velpatasvir.
Hepatitis B: HCV/HBV co-infected patients are at risk of Hepatitis B reactivation during or after DAA treatment and should be closely monitored.
Common Side Effects :
Most patients tolerate the medication well, but common adverse effects can include:Fatigue, Headache , Nausea or diarrhea Insomnia.
City Drug House Exporters provides:
Bulk supply for hospitals & distributors
Export to USA. Washington, INDIA
Regulatory documents (COA, MSDS, etc.)
Competitive pricing & reliable logistics
Contact for More Information :
📞 Contact City drug House Exporters from India
🌐 Websites:
https://www.citydrugexporters.com
📧 Email: citydrug123@gmail.com
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 9975390171
